- Denosumab‑associated jaw bone necrosis in cancer patients: retrospective descriptive case series study
-
Kang J, Kim S, Lim J, Kim J, Jin G, Lee Y, Lee E
- KMID: 2552530
- Maxillofac Plast Reconstr Surg.
- 2023;45(1):23.
- doi: 10.1186/s40902-023-00391-9
Background Denosumab (DMB) is a bone antiresorptive agent used to treat osteoporosis or metastatic cancer of the bones. However, denosumab-associated osteonecrosis of the jaw (DRONJ) has become a common complication... -
- CITED
-
- Close
- SHARE
-
- Close
